4FR logo

Faron Pharmaceuticals OyDB:4FR Stock Report

Market Cap €84.1m
Share Price
n/a
1Y-81.2%
7D1.4%
1D-1.2%
Portfolio Value
​
View

Faron Pharmaceuticals Oy

DB:4FR Stock Report

Market Cap: €84.1m

Faron Pharmaceuticals Oy (4FR) Stock Overview

Operates as a clinical stage drug discovery and development company. More details

4FR fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Risk Analysis

Earnings are forecast to decline by an average of 24.8% per year for the next 3 years

Shareholders have been substantially diluted in the past year

Makes less than USD$1m in revenue (€0)

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 more risk

4FR Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW425,311 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
425,311 investors already sharing narratives
View all narratives

Faron Pharmaceuticals Oy Competitors

Price History & Performance

Summary of share price highs, lows and changes for Faron Pharmaceuticals Oy
Historical stock prices
Current Share PriceUK£0.40
52 Week HighUK£2.37
52 Week LowUK£0.39
Beta1.12
1 Month Change-13.25%
3 Month Change-18.39%
1 Year Change-81.20%
3 Year Change-89.54%
5 Year Changen/a
Change since IPO-88.65%

Recent News & Updates

Recent updates

Shareholder Returns

4FRDE BiotechsDE Market
7D1.4%-1.5%1.0%
1Y-81.2%-4.5%4.7%

Return vs Industry: 4FR underperformed the German Biotechs industry which returned -3.9% over the past year.

Return vs Market: 4FR underperformed the German Market which returned 4.9% over the past year.

Price Volatility

Is 4FR's price volatile compared to industry and market?
4FR volatility
4FR Average Weekly Movement4.3%
Biotechs Industry Average Movement5.4%
Market Average Movement5.0%
10% most volatile stocks in DE Market11.6%
10% least volatile stocks in DE Market2.5%

Stable Share Price: 4FR has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: 4FR's weekly volatility has decreased from 12% to 4% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200336Juho Jalkanenfaron.com

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company’s lead product candidate is Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. It is also developing bexmarilimab for the treatment of hematological and solid tumor cancers; and in combination with care therapies, azacitidine, and other hypomethylating agents in relapsed/refractory myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

Faron Pharmaceuticals Oy Fundamentals Summary

How do Faron Pharmaceuticals Oy's earnings and revenue compare to its market cap?
4FR fundamental statistics
Market cap€84.11m
Earnings (TTM)-€16.34m
Revenue (TTM)n/a
0.0x
P/S Ratio
-5.1x
P/E Ratio

Is 4FR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4FR income statement (TTM)
Revenue€0
Cost of Revenue€0
Gross Profit€0
Other Expenses€16.34m
Earnings-€16.34m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-0.079
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio153.8%

How did 4FR perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/17 05:22
End of Day Share Price 2026/09/17 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Faron Pharmaceuticals Oy is covered by 10 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Klas PalinDNB Carnegie Commissioned Research
Patrick TrucchioH.C. Wainwright & Co.
Frans-Mikael RostedtInderes Oy